Review
Diffuse Large B-Cell Lymphoma
In: The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 85.
Affiliations
- PMID: 32091762
- Bookshelf ID: NBK553941
- DOI: 10.1007/978-3-030-02278-5_85
Item in Clipboard
Review
Diffuse Large B-Cell Lymphoma
Excerpt
Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of morphologically medium to large B-lymphoid cells. The most recent WHO classification of tumors of hematopoietic and lymphoid tissues (Swerdlow et al.
Copyright 2019, EBMT and the Author(s).
Sections
- 85.1. Definition and Epidemiology
- 85.2. Diagnosis
- 85.3. Classification
- 85.4. Risk Factors
- 85.5. First-Line Treatment
- 85.6. Second-Line Treatment
- 85.7. Autologous HSCT
- 85.8. Allogeneic HSCT
- 85.9. Therapeutic Algorithm Recommended by the Authors (See Fig. 85.1)
- 85.10. Long-Term Outcomes of Auto- and Allo-HSCT in Patients with R/R DLBCL (See Fig. 85.2)
- References
References
-
- Casasnovas RO, Ysebaert L, Thieblemont C, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130:1315–26. - PubMed
-
- Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076–88. - PubMed
-
- Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490–6. - PubMed
-
- Friedberg JW. How I treat double-hit lymphoma. Blood. 2017;130:590–6. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
